A clinical trail on the efficacy and safety of autologous DC-CIK cells infusion treatment in primary lung cancer patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-16010105

Enrollment

Unknown

Registered

2016-12-08

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary lung cancer

Interventions

A:Infusion of DC- CIK cells and supportive care

B:supportive care

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The patient was diagnosed with primary lung cancer by pathology; 2) Aged 18 to 80 years, KPS score=60 points, estimated survival time=12 months; 3) WBC=2.5×10^9/L, Hb=80g/L and PLT=50×10^9/L; 4) No severe organic or functional diseases; 5) Voluntary participation in the clinical trials and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women; 2) Poor body condition, cachexia or in combination with other fatal diseases; 3) Vital organs (heart, liver, kidney) function is serious dysfunction; 4) Patients received immunosuppressive drugs (cyclosporine A, etc.) or other immune treatment; 5) Active hepatitis B or hepatitis C virus infection; 6) patients infected by HIV; 7) patients with T cell lymphoma.

Design outcomes

Primary

Measure	Time frame
short-term effect: disease control rate of DCR (CR + PR +SD); Long-term effect: Progression-Free Srvival (PFS);Immune indeces;Quality of Life;Safety;	—

Countries

China

Contacts

Public ContactJun Ji

Dalian municipal central hospital

cancer-1976@hotmail.com+86 13998697244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026